Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Current Quarter	$-0.25	Next Quarter	$-0.22
Current Year	$-1.55	Next Year	$-1.09
QoQ Growth	+12.0%	YoY Growth	+29.7%
3Y EPS CAGR	N/A	Target Price	$7.00
Consensus	Buy	Upside	+376.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMEA	$1.47	-3.29%	957.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMEA	$1.47	-3.3%	957.31K
3
4
5
6

BMEA

BMEA

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Biomea Fusion Inc. Data in Excel

Get Biomea Fusion Inc. Data in Excel